Type 2 diabetes mellitus (T2DM) is closely associated with obesity. Lifestyle modification, including dietary modification, leads to weight loss, a crucial part of management of patients with T2DM. Evidence shows that treatment with Dapagliflozin leads to weight loss. However, there is a lack of in-depth studies exploring the body composition changes induced by Dapagliflozin in patients following low carbohydrate diet. Our aim was to undertake a detailed assessment of the appetitive and metabolic effects of Dapagliflozin in patients with T2DM. Participants had detailed metabolic studies, including indirect calorimetry (energy expenditure measurements), appetite assessment and quantification of body fat using BodPod in the Human Metabolism Research Unit; University Hospitals of Coventry and Warwickshire (UHCW), UK. The study duration is for 12 months; interestingly, preliminary data from 10 participants who completed 6 months follow-up showed statistically significant weight loss of 5.7 kg at month 6 (Figure 1). There was significant decrease in fat mass observed at month 3 (6.3kg) with no difference in muscle mass. There was no difference in energy expenditure before and after 12 months treatment with dapagliflozin. There was no change in self-reported appetite. These results indicate that low carbohydrate diet improves Dapagliflozin's potential for weight loss, with fat loss in particular.
P. Hanson: Other Relationship; Self; AstraZeneca, AstraZeneca. H. Randeva: None. T.M. Barber: None. J.P. OHare: None.
AstraZeneca; University Hospital of Coventry and Warwickshire